Polynovo Ltd
ASX:PNV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Polynovo Ltd
ASX:PNV
|
AU |
|
S
|
Smartcraft ASA
OSE:SMCRT
|
NO |
|
Clabo SpA
MIL:CLA
|
IT |
|
A
|
Aktia Bank Abp
OMXH:AKTIA
|
FI |
|
Pensana PLC
LSE:PRE
|
UK |
|
Brains Technology Inc
TSE:4075
|
JP |
|
Lefroy Exploration Ltd
ASX:LEX
|
VG |
|
Grocery Outlet Holding Corp
NASDAQ:GO
|
US |
|
NorthWest Healthcare Properties REIT
TSX:NWH.UN
|
CA |
|
Cavitation Technologies Inc
OTC:CVAT
|
US |
|
Telia Company AB
STO:TELIA
|
SE |
|
Yuuzoo Networks Group Corp
SGX:AFC
|
SG |
Polynovo Ltd
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
Polynovo Ltd. engages in the provision biodegradable medical devices. The company is headquartered in Melbourne, Victoria and currently employs 122 full-time employees. The Company’s principal activity is the development of medical devices for various applications. The Company’s products include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb technology. BTM is a man-made synthetic polymer that does not contain any biologic materials. BTM is a skin treatment. NovoSorb is a polymer, which is utilizes for the manufacture of novel medical devices, such as Biocompatible polymers. These biocompatible polymers are designed to support different functions of the body and then biodegrade into by-products that can be absorbed and excreted by the body. The company can be produced in a range of formats with different mechanical and degradation properties. In addition to NovoSorb BTM, they can be used for thermoplastic extrusions, filaments for weaving or knitting and as a solution for spray or dip coatings of other devices.
Strong Sales Growth: PolyNovo reported first-half sales of $68.2 million, up 26% year-on-year, with the U.S. leading at $51.7 million, up 25.3%.
Profitability Improvement: Adjusted EBITDA reached $4.7 million, up 82% on the prior period, despite some one-off items.
Gross Margin Impact: Gross margin for the half was 88.8%, affected by temporary manufacturing slowdowns, but is expected to exceed 90% for the full year.
Free Cash Flow Milestone: The company expects to generate free cash flow in the second half as new facility capex winds down.
Manufacturing Expansion: New facility offers up to 5x previous capacity, with operations ramping from July.
Product & Market Pipeline: Company is advancing PMA submission for NovoSorb BTM, targeting new indications, U.S. outpatient market entry, and expansion into Japan and China.
No Formal Guidance: Management reiterated they do not provide forward guidance due to ongoing variability, particularly in the burn segment.
